dapirolizumab pegol
dapirolizumab pegol: developed by 1 company · 1 clinical trial tracked.
dapirolizumab pegol evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect dapirolizumab pegol to BIIB; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could dapirolizumab pegol → BIIB affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
moderate-to-severe systemic lupus erythematosusSystemic Lupus Erythematosus
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| BIOGEN INC. (BIIB) moderate-to-severe systemic lupus erythematosus | Phase 3 |
Clinical Trials (1)
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) during the study
Interventionalopen760 targetStarted 2021-07Completion 2030-0850 sites · Argentina, Belgium, Bulgaria, Canada…UCB Biopharma SRL
Frequently asked questions
Who is developing dapirolizumab pegol?
dapirolizumab pegol is being developed by BIOGEN INC..
How many clinical trials involve dapirolizumab pegol?
BioSniper tracks 1 clinical trial involving dapirolizumab pegol.